These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 29616864)

  • 1. A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia.
    Redner RL; Beumer JH; Kropf P; Agha M; Boyiadzis M; Dorritie K; Farah R; Hou JZ; Im A; Lim SH; Raptis A; Sehgal A; Christner SM; Normolle D; Johnson DE
    Leuk Lymphoma; 2018 Nov; 59(11):2595-2601. PubMed ID: 29616864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged administration of all-trans retinoic acid in combination with intensive chemotherapy and G-CSF for adult acute myelogenous leukemia: single-centre pilot study in different risk groups.
    Bassan R; Chiodini B; Lerede T; Giussani U; Oldani E; Buelli M; Rossi A; Viero P; Rambaldi A; Barbui T
    Hematol J; 2002; 3(4):193-200. PubMed ID: 12189565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Src inhibitors, PP2 and dasatinib, increase retinoic acid-induced association of Lyn and c-Raf (S259) and enhance MAPK-dependent differentiation of myeloid leukemia cells.
    Congleton J; MacDonald R; Yen A
    Leukemia; 2012 Jun; 26(6):1180-8. PubMed ID: 22182854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dasatinib synergizes with ATRA to trigger granulocytic differentiation in ATRA resistant acute promyelocytic leukemia cell lines via Lyn inhibition-mediated activation of RAF-1/MEK/ERK.
    Ding M; Weng XQ; Sheng Y; Wu J; Liang C; Cai X
    Food Chem Toxicol; 2018 Sep; 119():464-478. PubMed ID: 29097117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial.
    Belhabri A; Thomas X; Wattel E; Chelghoum Y; Anglaret B; Vekhoff A; Reman O; Dombret H; Dhedin N; Michallet M; Fière D; Archimbaud E
    Hematol J; 2002; 3(1):49-55. PubMed ID: 11960396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphorylation of c-Cbl and p85 PI3K driven by all-trans retinoic acid and CD38 depends on Lyn kinase activity.
    Congleton J; Shen M; MacDonald R; Malavasi F; Yen A
    Cell Signal; 2014 Jul; 26(7):1589-97. PubMed ID: 24686085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
    Kuendgen A; Knipp S; Fox F; Strupp C; Hildebrandt B; Steidl C; Germing U; Haas R; Gattermann N
    Ann Hematol; 2005 Dec; 84 Suppl 1():61-6. PubMed ID: 16270213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies.
    Tayari MM; Santos HGD; Kwon D; Bradley TJ; Thomassen A; Chen C; Dinh Y; Perez A; Zelent A; Morey L; Cimmino L; Shiekhattar R; Swords RT; Watts JM
    Clin Cancer Res; 2021 Apr; 27(7):1893-1903. PubMed ID: 33495312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lyn, a tyrosine kinase closely linked to the differentiation status of primary acute myeloid leukemia blasts, associates with negative regulation of all-trans retinoic acid (ATRA) and dihydroxyvitamin D3 (VD3)-induced HL-60 cells differentiation.
    Iriyama N; Yuan B; Hatta Y; Takagi N; Takei M
    Cancer Cell Int; 2016; 16():37. PubMed ID: 27182202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia.
    Bug G; Ritter M; Wassmann B; Schoch C; Heinzel T; Schwarz K; Romanski A; Kramer OH; Kampfmann M; Hoelzer D; Neubauer A; Ruthardt M; Ottmann OG
    Cancer; 2005 Dec; 104(12):2717-25. PubMed ID: 16294345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia.
    Kuendgen A; Schmid M; Schlenk R; Knipp S; Hildebrandt B; Steidl C; Germing U; Haas R; Dohner H; Gattermann N
    Cancer; 2006 Jan; 106(1):112-9. PubMed ID: 16323176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. All-trans retinoic acid in association with low dose cytosine arabinoside in the treatment of acute myeoid leukemia in elderly patients.
    Di Febo A; Laurenti L; Falcucci P; Tosti ME; Fianchi L; Pagano L; Leone G
    Am J Ther; 2007; 14(4):351-5. PubMed ID: 17667210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
    Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
    Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
    Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
    Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological activity of all-trans-retinoic acid with and without tamoxifen and alpha-interferon 2a in breast cancer patients.
    Toma S; Raffo P; Nicolo G; Canavese G; Margallo E; Vecchio C; Dastoli G; Iacona I; Regazzi-Bonora M
    Int J Oncol; 2000 Nov; 17(5):991-1000. PubMed ID: 11029503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia: the APL92 study of the Japan Adult Leukemia Study Group (JALSG).
    Asou N; Adachi K; Tamura U; Kanamaru A; Kageyama S; Hiraoka A; Omoto E; Akiyama H; Tsubaki K; Saito K; Kuriyama K; Oh H; Kitano K; Miyawaki S; Takeyama U; Yamada O; Nishikawa K; Takahashi M; Matsuda S; Ohtake H; Ohno R
    Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S65-71. PubMed ID: 11587370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide.
    Jung YS; Cheong HJ; Kim SJ; Kim KH; Lee N; Park HS; Won JH
    Leuk Res; 2014 Aug; 38(8):977-82. PubMed ID: 24953245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma.
    Boorjian SA; Milowsky MI; Kaplan J; Albert M; Cobham MV; Coll DM; Mongan NP; Shelton G; Petrylak D; Gudas LJ; Nanus DM
    J Immunother; 2007 Sep; 30(6):655-62. PubMed ID: 17667529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Combination of interferon-alpha and all-trans-retinoic acid as a treatment for maintaining remission in high-risk group patients with acute myeloid leukemia].
    Parovichnikova EN; Savchenko VG; Isaev VG; Demidova IA; Ol'shanskaia IuV; Lapin VA; Cherepanova VV; Rekhtman GB; Perekatova TN
    Ter Arkh; 2001; 73(7):15-20. PubMed ID: 11523403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo use of all-trans retinoic acid prior to induction chemotherapy improves complete remission rate and increases rhodamine 123 uptake in patients with de novo acute myeloid leukemia.
    Ustün C; Beksac M; Dalva K; Koc H; Konuk N; Ilhan O; Ozcan M; Topcuoglu P; Sertkaya D; Hayran M
    Med Oncol; 2002; 19(1):59-67. PubMed ID: 12025892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.